Statement: a pathologic complete response was observed in less than 30% of the patients from the intervention group in the primary clinical trial
Primary_evidence: Outcome Measurement:    Pathologic Complete Response   [Not Specified]   Time frame: 22 weeks Results 1:    Arm/Group Title: Intervention Arm   Arm/Group Description: Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery   nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks   trastuzumab: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks   Doxorubicin: 60 MG/M2 every two weeks for a total of 4 cycles   cyclophosphamide: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)   Growth Factor Support: - All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.   - Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician.   Surgery: -After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.   -All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection.   Overall Number of Participants Analyzed: 32   Measure Type: Number   Unit of Measure: percentage of participants  26